Nattokinase for Cardiovascular Health: Evidence and Dosage

Nattokinase is a serine protease enzyme extracted from natto — a traditional Japanese fermented soybean dish — that has attracted significant research interest for cardiovascular health. Unlike most supplements that work through nutritional pathways, nattokinase functions as an enzyme: it directly degrades fibrin, the protein that forms the structural scaffold of blood clots. This is pharmacologically similar in principle to prescription thrombolytic drugs, though the magnitude of effect is substantially smaller.

The research on nattokinase is genuinely interesting. It is not a supplement to take casually, because its mechanism of action means it has real interactions with anticoagulant medications and carries specific contraindications. Understanding both the benefits and the risks is essential.

What nattokinase is and how it works

Natto has been consumed in Japan for over a thousand years. In 1987, researcher Hiroyuki Sumi discovered that natto contained an enzyme with thrombolytic (clot-dissolving) activity when he tested various foods against fibrin clots in a laboratory. Nattokinase is now extracted and standardized from Bacillus subtilis var. natto, the bacteria that ferments soybeans to make natto.

Nattokinase's primary mechanisms:

Fibrinolysis: Nattokinase cleaves fibrin directly. It acts on the same substrate as the body's own plasmin enzyme. It also stimulates the production of endogenous tissue plasminogen activator (t-PA) and degrades plasminogen activator inhibitor-1 (PAI-1), both of which further amplify the body's own clot-dissolving activity.

Anti-platelet aggregation: Some research suggests nattokinase reduces platelet clumping, which is a separate mechanism from fibrinolysis but also relevant to clot prevention.

Blood pressure reduction: Nattokinase inhibits angiotensin-converting enzyme (ACE) in laboratory studies. ACE inhibition is the mechanism of a major class of antihypertensive drugs (lisinopril, enalapril), though nattokinase's ACE inhibitory activity is substantially weaker.

Arterial plaque effects: A clinical trial found reductions in arterial plaque, possibly related to fibrin's role in plaque stability and progression.

Dosage and units: understanding FU

Nattokinase activity is measured in fibrinolytic units (FU), not milligrams of powder. This distinction matters because different products may list either FU or mg, and the potency per mg can vary significantly depending on purity and manufacturing.

Standard clinical dose: 2,000 FU/day, typically divided into two 1,000 FU doses.

Common product formats:

• 2,000 FU capsules (taken as 1 capsule daily or split as 1,000 FU twice daily)
• 100mg capsules (FU content should be specified — typically 2,000 FU per 100mg, but verify)

Many studies used 100mg of standardized nattokinase providing 2,000 FU. Some protocols used twice that amount (200mg/4,000 FU) without significant adverse effects.

If a supplement label lists only milligrams without FU, the fibrinolytic activity is unverifiable — this is a quality flag.

Blood pressure: the evidence

A 2008 randomized, double-blind, placebo-controlled trial (n=86) published in Hypertension Research gave 2,000 FU/day of nattokinase to hypertensive patients for 8 weeks. Results:

• Systolic BP reduced by 5.55 mmHg more than placebo
• Diastolic BP reduced by 2.84 mmHg more than placebo
• No significant adverse effects

These are modest but real reductions. For reference, ACE inhibitor drugs typically reduce BP by 8-10 mmHg systolic in clinical trials — nattokinase produces roughly half that effect. For mild hypertension (systolic 130-140 mmHg), a 5 mmHg reduction is clinically meaningful. For more significant hypertension, nattokinase is unlikely to be sufficient as a sole intervention but may complement lifestyle changes or reduce medication requirements.

Fibrinolytic effects: the evidence

A 2009 study tested nattokinase in 12 healthy volunteers using sensitive markers of clot formation and dissolution. Single-dose 2,000 FU nattokinase significantly increased fibrinolytic activity over 8 hours, with peak effects at 2-4 hours post-ingestion. Euglobulin fibrinolytic activity, fibrin/fibrinogen degradation products, and factor VIII (a clotting factor) were all affected.

A 2017 study in Scientific Reports (n=1,062) found that 6 months of nattokinase supplementation at 6,000 FU/day reduced atherosclerotic plaque volume by 36.6% compared to 11.5% in the statin group. This is a striking result but must be interpreted cautiously — it was an open-label, non-randomized study with methodological limitations.

A rigorous meta-analysis published in 2023 in Clinical Nutrition analyzed 11 eligible studies and concluded nattokinase significantly reduced SBP, DBP, total cholesterol, LDL, and triglycerides compared to controls, while increasing HDL. Effect sizes were generally modest but statistically significant.

When NOT to use nattokinase

This is critical information. Nattokinase's anticoagulant mechanism creates significant risks in specific contexts:

Absolute contraindications:

• Patients on anticoagulants (warfarin/Coumadin, apixaban/Eliquis, rivaroxaban/Xarelto, dabigatran/Pradaxa): Nattokinase can cause additive anticoagulation, dangerously increasing bleeding risk. This is a serious drug interaction.
• Patients on antiplatelet drugs (clopidogrel/Plavix, aspirin at antiplatelet doses): Similar additive bleeding risk
• Active bleeding disorders or known coagulopathies
• Pre-surgery: Discontinue at least 2 weeks before any surgical procedure
• Recent stroke history: The type of stroke matters critically — ischemic strokes (caused by clots) are theoretically helped by anticoagulation, but hemorrhagic strokes (caused by bleeding) would be worsened. Nattokinase should never be used post-stroke without physician evaluation.

Strong precautions:

• Pregnancy: Data insufficient, avoid
• Peptic ulcer disease: Anticoagulant effect could worsen GI bleeding
• Those with a history of hemorrhagic events

A clear principle: If you take any prescription blood thinner or antiplatelet drug, do not add nattokinase without explicit physician approval.

Nattokinase vs. prescription alternatives

| | Nattokinase (2,000-6,000 FU/day) | Warfarin | Aspirin (antiplatelet) | |---|---|---|---| | Mechanism | Fibrinolysis + ACE inhibition | Vitamin K antagonist | COX inhibition | | Blood pressure effect | Modest (5-6 mmHg SBP) | None | Minimal | | Clot prevention | Moderate fibrinolytic activity | Strong | Antiplatelet only | | Monitoring required | No | Yes (INR weekly/monthly) | No | | Bleeding risk | Moderate (less than warfarin alone) | Higher | Lower | | Reversal agent | None proven | Vitamin K | Time |

For primary prevention in healthy adults with mild cardiovascular risk, nattokinase occupies a reasonable risk-benefit position. For secondary prevention after cardiac events, prescription anticoagulants under medical supervision are standard of care — nattokinase should not replace them.

Timing and practical use

Timing: Nattokinase is best taken on an empty stomach, either 30 minutes before a meal or 2 hours after. Food — particularly protein — may partially inhibit the enzyme before it is absorbed. Some practitioners recommend a morning dose on an empty stomach and an evening dose 2 hours after dinner.

Temperature: Nattokinase is a protein enzyme that is denatured by heat. Do not open capsules and add to hot foods or drinks.

Storage: Keep at room temperature away from light and humidity. Refrigeration not required but extends shelf life.

Reputable brands: Doctor's Best (one of the most-studied brands in trials), Allergy Research Group, Jarrow Formulas. Look for FU activity stated on the label.

The bottom line

Nattokinase at 2,000 FU/day has genuine cardiovascular evidence: modest but real blood pressure reductions (5-6 mmHg systolic), measurable fibrinolytic activity, and lipid improvements in meta-analysis. Its mechanism — direct fibrin degradation and ACE inhibition — is pharmacologically distinct from most supplements and is supported by specific clinical trial data. For healthy adults interested in cardiovascular health optimization, it is one of the more interesting and evidence-supported options. However, its anticoagulant activity creates serious drug interactions with prescription blood thinners, and it is absolutely contraindicated in patients on warfarin, DOACs, or clopidogrel. Pre-surgical discontinuation is essential. Anyone with cardiovascular disease, on blood thinners, or with a stroke history should not use nattokinase without physician clearance.

---

Track your supplements. Use Optimize free.

Related Articles

• Nattokinase for Blood Clot Prevention: Evidence and Safety Concerns